{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:16:22Z","timestamp":1791821782959,"version":"4.3.4"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["3\/1\/3\/PDF(8)\/2013"],"award-info":[{"award-number":["3\/1\/3\/PDF(8)\/2013"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["tuberculosisjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.tube.2017.04.008","type":"journal-article","created":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T00:45:22Z","timestamp":1492821922000},"page":"96-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era"],"prefix":"10.1016","volume":"105","author":[{"given":"Ameeruddin","family":"Nusrath Unissa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke Elizabeth","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2017.04.008_bib1","author":"World Health Organization"},{"key":"10.1016\/j.tube.2017.04.008_bib2","unstructured":"Centers for Disease Control and Prevention, Treatment of tuberculosis, http:\/\/www.cdc.gov\/tb\/topic\/treatment\/default.htm accessed on 2.03.16."},{"key":"10.1016\/j.tube.2017.04.008_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(10)62173-3","article-title":"Tuberculosis","volume":"378","author":"Lawn","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2017.04.008_bib4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ng.2735","article-title":"Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.tube.2017.04.008_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng.2878","article-title":"Evolution and transmission of drug-resistant tuberculosis in a Russian population","volume":"46","author":"Casali","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.tube.2017.04.008_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/tuld.1998.0002","article-title":"Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update","volume":"79","author":"Ramaswamy","year":"1998","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/rr54","article-title":"The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis","volume":"2","author":"Somoskovi","year":"2001","journal-title":"Respir Res"},{"key":"10.1016\/j.tube.2017.04.008_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng.1038","article-title":"Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes","volume":"44","author":"Comas","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.tube.2017.04.008_bib9","doi-asserted-by":"crossref","first-page":"e0117771","DOI":"10.1371\/journal.pone.0117771","article-title":"Whole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from Pakistan","volume":"10","author":"Ali","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2017.04.008_bib10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/ng.2747","article-title":"Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis","volume":"45","author":"Farhat","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.tube.2017.04.008_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1099\/00222615-47-3-189","article-title":"The rapid diagnosis of isoniazid and rifampin resistance in Mycobacterium tuberculosis, a molecular story","volume":"47","author":"Drobniewski","year":"1998","journal-title":"J\u00a0Med Microbiol"},{"issue":"7","key":"10.1016\/j.tube.2017.04.008_bib12","doi-asserted-by":"crossref","first-page":"e0133869","DOI":"10.1371\/journal.pone.0133869","article-title":"A\u00a0global perspective on pyrazinamide resistance: systematic review and meta-analysis","volume":"10","author":"Whitfield","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2017.04.008_bib13","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1038\/emi.2014.17","article-title":"The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?","volume":"2014","author":"Koch","year":"2014","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.tube.2017.04.008_bib14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis","volume":"333","author":"Shi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.tube.2017.04.008_bib15","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1128\/JCM.00620-12","article-title":"Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA","volume":"50","author":"Alexander","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib16","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1038\/emi.2013.38","article-title":"Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis","volume":"2","author":"Zhang","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.tube.2017.04.008_bib17","article-title":"Mechanisms of pyrazinamide action and resistance","volume":"2","author":"Zhang","year":"2013","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.tube.2017.04.008_bib18","first-page":"84","article-title":"Antimycobacterial drugs","volume":"9","author":"Heifets","year":"1994","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.tube.2017.04.008_bib19","first-page":"977","article-title":"Short-course drug therapy for tuberculosis","volume":"5","author":"Stratton","year":"1986","journal-title":"Clin Pharm"},{"issue":"6","key":"10.1016\/j.tube.2017.04.008_bib20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0092-8674(00)81515-9","article-title":"Crystal structure of Thermus aquaticus core RNA polymerase at 3.3 A resolution","volume":"98","author":"Zhang","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.tube.2017.04.008_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1369-5274(03)00036-5","article-title":"RNA polymerase holoenzyme: structure, function and biological implications","volume":"6","author":"Borukhov","year":"2003","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.tim.2007.12.006","article-title":"RNA polymerase: the vehicle of transcription","volume":"16","author":"Borukhov","year":"2008","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial rna polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.tube.2017.04.008_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1101\/gr.128678.111","article-title":"Microevolution of extensively drug-resistant tuberculosis in Russia","volume":"22","author":"Casali","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.tube.2017.04.008_bib25","series-title":"Bacterial RNA polymerase subunits and genes","author":"Burgess","year":"1987"},{"key":"10.1016\/j.tube.2017.04.008_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0022-2836(88)90517-7","article-title":"Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance","volume":"202","author":"Jin","year":"1988","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.tube.2017.04.008_bib27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0140-6736(93)90417-F","article-title":"Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis","volume":"341","author":"Telenti","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2017.04.008_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jmgm.2016.04.005","article-title":"Insights into RpoB clinical mutants in mediating rifampicin resistance in Mycobacterium tuberculosis","volume":"67","author":"Nusrath Unissa","year":"2016","journal-title":"J\u00a0Mol Graph Model"},{"key":"10.1016\/j.tube.2017.04.008_bib29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/1471-2334-14-479","article-title":"Molecular detection and characterization of resistant genes in Mycobacterium tuberculosis complex from DNA isolated from tuberculosis patients in the Eastern Cape province South Africa","volume":"14","author":"Bhembe","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib30","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/JCM.05171-11","article-title":"Molecular characteristics of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Vietnam","volume":"50","author":"Minh","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijmyco.2014.06.004","article-title":"Mutation pattern in rifampicin resistance determining region of rpoB gene in multidrug-resistant Mycobacterium tuberculosis isolates from Pakistan","volume":"3","author":"Qazi","year":"2014","journal-title":"Int J Mycobacteriol"},{"key":"10.1016\/j.tube.2017.04.008_bib32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/jac\/dkp292","article-title":"Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing","volume":"64","author":"Valvatne","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib33","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1590\/0074-02760150100","article-title":"Molecular profiling of drug resistant isolates of Mycobacterium tuberculosis in the state of Santa Catarina, southern Brazil","volume":"110","author":"Prim","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.tube.2017.04.008_bib34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jac\/dkp183","article-title":"Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Ontario, Canada","volume":"64","author":"Bolotin","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2013.02.035","article-title":"Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea","volume":"76","author":"Jnawali","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib36","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1469-0691.2010.03267.x","article-title":"Detection of rpoB, katG and inhA gene mutations in Mycobacterium tuberculosis clinical isolates from Chongqing as determined by microarray","volume":"16","author":"Yao","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.tube.2017.04.008_bib37","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1128\/JCM.r00548-09","article-title":"High-level rifampin resistance correlates with multiple mutations in the rpoB gene of pulmonary tuberculosis isolates from the Afghanistan border of Iran","volume":"47","author":"Bahrmand","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4172\/2161-1068.1000156","article-title":"Detection of mutations in rpob gene of clinically isolated M. tuberculosis by DNA sequencing","volume":"4","author":"Sharma","year":"2014","journal-title":"Mycobact Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1469-0691.2008.01951.x","article-title":"Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection","volume":"14","author":"Prammananan","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.tube.2017.04.008_bib40","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1469-0691.2004.00917.x","article-title":"In\u00a0vitro activity of rifabutin against rifampicin resistant Mycobacterium tuberculosis isolates with known rpoB mutations","volume":"10","author":"Cavusoglu","year":"2004","journal-title":"Clin Microb Infect"},{"key":"10.1016\/j.tube.2017.04.008_bib41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/cis487","article-title":"Efficacy Subgroup, RESIST-TB. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis","volume":"55","author":"Dooley","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib42","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/AAC.01474-06","article-title":"Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib43","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1128\/AAC.43.5.1230","article-title":"Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study","volume":"43","author":"Keung","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib44","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2165\/11538170-000000000-00000","article-title":"Drugs in development for tuberculosis","volume":"70","author":"Ginsberg","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.tube.2017.04.008_bib45","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1086\/313876","article-title":"Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection","volume":"30","author":"Shoen","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib46","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1128\/AAC.40.11.2655","article-title":"Comparative antimycrobial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations","volume":"40","author":"Moghazeh","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib47","first-page":"53","article-title":"Current status and perspectives on the development of rifamycin derivative antibiotics","volume":"4","author":"Hidaka","year":"1999","journal-title":"Kekkaku"},{"key":"10.1016\/j.tube.2017.04.008_bib48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0041-3879(87)90053-5","article-title":"In\u00a0vitro activity of new rifamycins against rifampicin resistant Mycobacterium tuberculosis and MAIS-complex Mycobacteria","volume":"68","author":"Dickinson","year":"1987","journal-title":"Tubercle"},{"key":"10.1016\/j.tube.2017.04.008_bib49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0041-3879(87)90054-7","article-title":"In\u00a0vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis","volume":"68","author":"Dickinson","year":"1987","journal-title":"Tubercle"},{"key":"10.1016\/j.tube.2017.04.008_bib50","first-page":"626","article-title":"Bactericidal activity in\u00a0vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis","volume":"141","author":"Heifets","year":"1990","journal-title":"Amer J Respir Crit Care Medi"},{"key":"10.1016\/j.tube.2017.04.008_bib51","doi-asserted-by":"crossref","first-page":"e1001061","DOI":"10.1371\/journal.pmed.1001061","article-title":"Comparison of Xpert MTB\/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study","volume":"8","author":"Scott","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.tube.2017.04.008_bib52","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/JCM.00521-07","article-title":"Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens","volume":"45","author":"Hillemann","year":"2007","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib53","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1128\/JCM.01229-09","article-title":"Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones","volume":"47","author":"Bravo","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib54","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.pmed.1000002","article-title":"Tuberculosis drug resistance mutation database","volume":"6","author":"Sandgren","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.tube.2017.04.008_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-015-0164-0","article-title":"Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences","volume":"7","author":"Coll","year":"2015","journal-title":"Genome Med"},{"key":"10.1016\/j.tube.2017.04.008_bib56","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1128\/AAC.49.3.1229-1231.2005","article-title":"Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany","volume":"49","author":"Hillemann","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib57","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1128\/JCM.00081-09","article-title":"Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens","volume":"47","author":"Hillemann","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib58","unstructured":"GeneXpert System. Molecular diagnostics made fast, accurate and easy. http:\/\/www.cepheid.com\/systems-and-software\/genexpert-system."},{"key":"10.1016\/j.tube.2017.04.008_bib59","author":"WHO"},{"key":"10.1016\/j.tube.2017.04.008_bib60","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMc1413930","article-title":"Detection of drug-resistant tuberculosis by Xpert MTB\/RIF in Swaziland","volume":"372","author":"Sanchez-Padilla","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tube.2017.04.008_bib61","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1128\/JCM.03005-13","article-title":"Comparison of Xpert MTB\/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis","volume":"52","author":"Rufai","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib62","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib63","first-page":"461","article-title":"Pyrazinamide susceptibility and amidase activity of tubercle bacilli","volume":"95","author":"Konno","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib64","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2017.04.008_bib65","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1128\/JB.181.7.2044-2049.1999","article-title":"Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide","volume":"181","author":"Zhang","year":"1999","journal-title":"J\u00a0Bacteriol"},{"key":"10.1016\/j.tube.2017.04.008_bib66","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1128\/AAC.00967-15","article-title":"Uncoupling environmental pH and intrabacterial acidification from pyrazinamide susceptibility in Mycobacterium tuberculosis","volume":"59","author":"Peterson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib67","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.01370-15","article-title":"Selective inactivity of pyrazinamide against tuberculosis in C3HeB\/FeJ mice is best explained by neutral pH of caseum","volume":"60","author":"Lanoix","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib68","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/imr.12252","article-title":"Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses","volume":"264","author":"Lenaerts","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.tube.2017.04.008_bib69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","article-title":"Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in Mycobacterium tuberculosis infected C3HeB\/FeJ. Mice","volume":"2","author":"Irwin","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib70","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/BF01779121","article-title":"Nekrose und autolyse. Beitrag Zur Kenntnis der dystrophischen verkalkung","volume":"13","author":"Koller","year":"1934","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.tube.2017.04.008_bib71","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1099\/jmm.0.45639-0","article-title":"Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis","volume":"53","author":"Wade","year":"2004","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib72","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/jac\/dkh042","article-title":"Iron enhances the antituberculous activity of pyrazinamide","volume":"53","author":"Somoskovi","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib73","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1742-4658.2007.06241.x","article-title":"Characterization of Mycobacterium tuberculosis nicotinamidase\/pyrazinamidase","volume":"275","author":"Zhang","year":"2008","journal-title":"FEBS J"},{"key":"10.1016\/j.tube.2017.04.008_bib74","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/79558","article-title":"Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis","volume":"6","author":"Zimhony","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2017.04.008_bib75","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1128\/JB.184.8.2167-2172.2002","article-title":"Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I","volume":"184","author":"Boshoff","year":"2002","journal-title":"J\u00a0Bacteriol"},{"key":"10.1016\/j.tube.2017.04.008_bib76","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1128\/AAC.00529-10","article-title":"Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy","volume":"54","author":"Baughn","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib77","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1128\/AAC.42.2.462","article-title":"In\u00a0vitro antimycobacterial activity of 5 chloropyrazinamide","volume":"42","author":"Cynamon","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib78","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/cbdd.12684","article-title":"A\u00a0note on derivatives of isoniazid, rifampicin, and pyrazinamide showing activity against resistant Mycobacterium tuberculosis","volume":"87","author":"Nusrath Unissa","year":"2016","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"10.1016\/j.tube.2017.04.008_bib79","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/JCM.01903-13","article-title":"Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from Southern China","volume":"52","author":"Tan","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib80","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/nm765","article-title":"A\u00a0pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis","volume":"8","author":"Sambandamurthy","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2017.04.008_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2014.61","article-title":"Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis","volume":"3","author":"Shi","year":"2014","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"10.1016\/j.tube.2017.04.008_bib82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.advms.2015.09.007","article-title":"Pyrazinamide resistance in Mycobacterium tuberculosis: review and update","volume":"61","author":"Njire","year":"2016","journal-title":"Adv Med Sci"},{"issue":"9","key":"10.1016\/j.tube.2017.04.008_bib83","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/acsinfecdis.6b00070","article-title":"Pyrazinamide resistance is caused by two distinct mechanisms: prevention of coenzyme a depletion and loss of virulence factor synthesis","volume":"2","author":"Gopal","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib84","doi-asserted-by":"crossref","first-page":"7258","DOI":"10.1128\/AAC.04028-14","article-title":"Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide","volume":"58","author":"Dillon","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib85","doi-asserted-by":"crossref","first-page":"604","DOI":"10.5588\/ijtld.11.0376","article-title":"Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec","volume":"16","author":"Yee","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib86","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/cit452","article-title":"Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009","volume":"57","author":"Kurbatova","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib87","doi-asserted-by":"crossref","first-page":"e95645","DOI":"10.1371\/journal.pone.0095645","article-title":"Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California","volume":"9","author":"Budzik","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2017.04.008_bib88","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1128\/AAC.41.3.636","article-title":"Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms","volume":"41","author":"Sreevatsan","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib89","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1471-2334-11-240","article-title":"Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan","volume":"11","author":"Chiu","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib90","first-page":"14","article-title":"Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene","author":"Bhuju","year":"2013","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.tube.2017.04.008_bib91","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5588\/ijtld.14.0305","article-title":"Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan","volume":"19","author":"Akhmetova","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib92","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1469-0691.2009.03078.x","article-title":"Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan","volume":"16","author":"Ando","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.tube.2017.04.008_bib93","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/mdr.2009.0066","article-title":"Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran","volume":"15","author":"Doustdar","year":"2009","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.tube.2017.04.008_bib94","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.3390\/ijms11072670","article-title":"Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of Mycobacterium tuberculosis from South India","volume":"11","author":"Muthaiah","year":"2010","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tube.2017.04.008_bib95","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.meegid.2012.12.013","article-title":"Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico","volume":"19","author":"Cuevas-Cordoba","year":"2013","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.tube.2017.04.008_bib96","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1128\/JCM.00973-08","article-title":"Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates","volume":"46","author":"Mphahlele","year":"2008","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib97","first-page":"1430","article-title":"Mutations found in the pncA gene of Mycobacterium tuberculosis in clinical pyrazinamide-resistant isolates from a local region of China","volume":"37","author":"Zhang","year":"2009","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.tube.2017.04.008_bib98","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/1469-0691.12696","article-title":"Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm","volume":"20","author":"Simons","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.tube.2017.04.008_bib99","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1046\/j.1365-2958.1998.01038.x","article-title":"DNA repair in Mycobacterium tuberculosis. What have we learnt from the genome sequence?","volume":"29","author":"Mizrahi","year":"1998","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib100","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1128\/AAC.43.7.1761","article-title":"Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA","volume":"43","author":"Lemaitre","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib101","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/bj3530453","article-title":"Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis","volume":"353","author":"Lemaitre","year":"2001","journal-title":"Biochem J"},{"key":"10.1016\/j.tube.2017.04.008_bib102","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18000\/ijabeg.10010","article-title":"In silico studies on modeling of wild type and mutants of pyrazinamidase and docking with pyrazinamidase from Mycobacterium tuberculosis","volume":"1","author":"Nusrath Unissa","year":"2007","journal-title":"Int J Appl Bioeng"},{"key":"10.1016\/j.tube.2017.04.008_bib103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.6026\/97320630004024","article-title":"Insight to pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking","volume":"4","author":"Nusrath Unissa","year":"2009","journal-title":"Bioinformation"},{"key":"10.1016\/j.tube.2017.04.008_bib104","doi-asserted-by":"crossref","first-page":"e15785","DOI":"10.1371\/journal.pone.0015785","article-title":"Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide","volume":"6","author":"Petrella","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2017.04.008_bib105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.6026\/97320630006335","article-title":"Structure-Activity relationship in mutated pyrazinamidases from Mycobacterium tuberculosis","volume":"6","author":"Quiliano","year":"2011","journal-title":"Bioinformation"},{"key":"10.1016\/j.tube.2017.04.008_bib106","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1128\/AAC.05385-11","article-title":"Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis","volume":"56","author":"Stoffels","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib107","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1073\/pnas.93.10.4787","article-title":"Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides","volume":"93","author":"Azad","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2017.04.008_bib108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diagmicrobio.2004.01.001","article-title":"Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray","volume":"49","author":"Wade","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.tube.2017.04.008_bib109","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1128\/JCM.00352-07","article-title":"Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains","volume":"45","author":"Sekiguchi","year":"2007","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib110","series-title":"Tuberculosis diagnostics technology and market landscape","author":"UNITAID","year":"2014"},{"key":"10.1016\/j.tube.2017.04.008_bib111","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jgar.2016.04.008","article-title":"Whole-genome sequencing of multidrug-resistant Mycobacterium tuberculosis isolates from Myanmar","volume":"6","author":"Aung","year":"2016","journal-title":"J\u00a0Glob Antimicrob Resist"},{"issue":"10","key":"10.1016\/j.tube.2017.04.008_bib112","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1128\/AAC.00630-11","article-title":"Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses","volume":"55","author":"Chang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib113","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00204-15","article-title":"Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates","volume":"59","author":"Ramirez-Busby","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.04.008_bib114","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"Cole","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.tube.2017.04.008_bib115","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.tig.2012.11.005","article-title":"The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis","volume":"29","author":"Muller","year":"2013","journal-title":"Trends Genet"},{"key":"10.1016\/j.tube.2017.04.008_bib116","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tube.2011.11.003","article-title":"Mycobacterium tuberculosis\u2013heterogeneity revealed through whole genome sequencing","volume":"92","author":"Ford","year":"2012","journal-title":"Tuberc (Edinb)"},{"key":"10.1016\/j.tube.2017.04.008_bib117","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1473-3099(12)70277-3","article-title":"Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study","volume":"13","author":"Walker","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.tube.2017.04.008_bib118","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1469-0691.2008.02685.x","article-title":"Fitness cost of drug resistance in Mycobacterium tuberculosis","volume":"15","author":"Gagneux","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.tube.2017.04.008_bib119","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrmicro2319","article-title":"Antibiotic resistance and its cost: is it possible to reverse resistance?","volume":"8","author":"Andersson","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tube.2017.04.008_bib120","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(13)70254-6","article-title":"Molecular methods for tuberculosis trials: time for whole-genome sequencing?","volume":"1","author":"Menzies","year":"2013","journal-title":"Lancet Respir Med"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979216303705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979216303705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T16:04:25Z","timestamp":1658937865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979216303705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":120,"alternative-id":["S1472979216303705"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2017.04.008","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2017.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}